Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-jbqgn Total loading time: 0 Render date: 2024-07-02T05:38:36.788Z Has data issue: false hasContentIssue false

Chapter 10 - Acute Disseminated Encephalomyelitis and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

from Section 3 - Specific Syndromes and Diseases

Published online by Cambridge University Press:  27 January 2022

Josep Dalmau  and
Francesc Graus
Josep Dalmau
Affiliation:
Universitat de Barcelona
Francesc Graus
Affiliation:
Universitat de Barcelona
Get access

Summary

This chapter focuses on the MOG-antibody-associated disease as a distinct neurological disorder that includes several demyelinating syndromes, and it follows a monophasic or more frequently a relapsing–remitting course. In children, MOG antibody-associated disease usually presents as acute disseminated encephalomyelitis (ADEM), ADEM variants, or encephalitis that may present with seizures and isolated or predominant cortical hyperintense lesions in FLAIR MRI studies (FLAMES). In teenagers and adults the common clinical presentation is optic neuritis, myelitis, or brainstem syndromes. Some of the patients fulfil criteria of neuromyelitis optica spectrum disorders (NMOSD). Persistence of MOG antibodies is common in patients with relapses. The optimal treatment to prevent relapses has not been established. ADEM is the most frequent autoimmune encephalitis in children. The syndrome was characterized before the description of MOG antibodies and associates with distinct clinical and neuroimaging features. Brain MRI shows multiple hyperintense T2 lesions similar to those seen in anti-GABAaR encephalitis. As occur with NMOSD, ADEM is probably caused by different pathogenic mechanisms as MOG antibodies are only found in ~60% of patients. Besides MOG antibody-associated disease there are two other antibody-associated neurological syndromes that target oligodendrocytes as part of an immune attack: anti-NMDAR encephalitis and paraneoplastic encephalomyelitis with CRMP5 antibodies.

Keywords

Acute disseminated encephalomyelitis (ADEM)myelin oligodendrocyte glycoprotein (MOG) antibody-associated diseaseanti-GABAaR encephalitisneuromyelitis optica spectrum disorders (NMOSD)FLAIR-hyperintense lesions in anti-MOG associated encephalitis with seizures (FLAMES)anti-NMDAR encephalitisparaneoplastic encephalomyelitis and CRMP5 antibodies
Type
Chapter
Information
Autoimmune Encephalitis and Related Disorders of the Nervous System , pp. 290 - 314
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Reindl, M, Waters, P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019;15:89–102.CrossRefGoogle ScholarPubMed
Jarius, S, Wandinger, KP, Borowski, K, Stoecker, W, Wildemann, B. Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg 2012;114:331–335.Google Scholar
Matute, C, Palma, A, Serrano-Regal, MP, et al. N-methyl-D-aspartate receptor antibodies in autoimmune encephalopathy alter oligodendrocyte function. Ann Neurol 2020;87:670–676.Google Scholar
Spadaro, M, Winklmeier, S, Beltran, E, et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol 2018;84:315–328.CrossRefGoogle ScholarPubMed
Hillebrand, S, Schanda, K, Nigritinou, M, et al. Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat. Acta Neuropathol 2019;137:467–485.Google Scholar
Wingerchuk, DM, Banwell, B, Bennett, JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–189.Google Scholar
Dubey, D, Pittock, SJ, Kelly, CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 2018;83:166–177.Google Scholar
Britton, PN, Dale, RC, Blyth, CC, et al. Causes and clinical features of childhood encephalitis: a multicenter, prospective cohort study. Clin Infect Dis 2020;70:2517–2526.CrossRefGoogle ScholarPubMed
Krupp, LB, Banwell, B, Tenembaum, S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007;68:S7–12.Google Scholar
Cole, J, Evans, E, Mwangi, M, Mar, S. Acute disseminated encephalomyelitis in children: an updated review based on current diagnostic criteria. Pediatr Neurol 2019;100:26–34.Google Scholar
Pohl, D, Alper, G, Van Haren, K, et al. Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome. Neurology 2016;87:S38–S45.CrossRefGoogle Scholar
Koelman, DL, Mateen, FJ. Acute disseminated encephalomyelitis: current controversies in diagnosis and outcome. J Neurol 2015;262:2013–2024.Google Scholar
Van Bogaert, L. Post-infectious encephalomyelitis and multiple sclerosis: the significance of perivenous encephalomyelitis. J Neuropathol Exp Neurol 1950;9:219–249.Google Scholar
Torisu, H, Kira, R, Ishizaki, Y, et al. Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 2010;32:454–462.CrossRefGoogle ScholarPubMed
Banwell, B, Kennedy, J, Sadovnick, D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009;72:232–239.Google Scholar
Leake, JA, Albani, S, Kao, AS, et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004;23:756–764.CrossRefGoogle ScholarPubMed
Pohl, D, Hennemuth, I, von Kries, R, Hanefeld, F. Paediatric multiple sclerosis and acute disseminated encephalomyelitis in Germany: results of a nationwide survey. Eur J Pediatr 2007;166:405–412.Google Scholar
Yamaguchi, Y, Torisu, H, Kira, R, et al. A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology 2016;87:2006–2015.Google Scholar
Otallah, S. Acute disseminated encephalomyelitis in children and adults: a focused review emphasizing new developments. Mult Scler 2021:27:1153–1160.CrossRefGoogle ScholarPubMed
Chen, Y, Ma, F, Xu, Y, Chu, X, Zhang, J. Incidence of acute disseminated encephalomyelitis in the Jiangsu province of China, 2008–2011. Mult Scler J Exp Transl Clin 2015;1:2055217315594831.Google ScholarPubMed
Koelman, DL, Chahin, S, Mar, SS, et al. Acute disseminated encephalomyelitis in 228 patients: a retrospective, multicenter US study. Neurology 2016;86:2085–2093.Google Scholar
Dale, RC, de Sousa, C, Chong, WK, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000;123:2407–2422.CrossRefGoogle ScholarPubMed
Sejvar, JJ, Kohl, KS, Bilynsky, R, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25:5771–5792.Google Scholar
Novi, G, Rossi, T, Pedemonte, E, et al. Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm 2020;7:e797.Google Scholar
Parsons, T, Banks, S, Bae, C, et al. COVID-19-associated acute disseminated encephalomyelitis (ADEM). J Neurol 2020:267:2799–2802.CrossRefGoogle ScholarPubMed
Karussis, D, Petrou, P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 2014;13:215–224.CrossRefGoogle ScholarPubMed
Chen, Y, Ma, F, Xu, Y, Chu, X, Zhang, J. Vaccines and the risk of acute disseminated encephalomyelitis. Vaccine 2018;36:3733–3739.Google Scholar
Krupp, LB, Tardieu, M, Amato, MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013;19:1261–1267.CrossRefGoogle Scholar
Erol, I, Ozkale, Y, Alkan, O, Alehan, F. Acute disseminated encephalomyelitis in children and adolescents: a single center experience. Pediatr Neurol 2013;49:266–273.Google Scholar
Ketelslegers, IA, Visser, IE, Neuteboom, RF, et al. Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children. Mult Scler 2011;17:441–448.Google Scholar
Koelman, DL, Benkeser, DC, Xu, Y, et al. Acute disseminated encephalomyelitis in China, Singapore and Japan: a comparison with the USA. Eur J Neurol 2017;24:391–396.Google Scholar
Boesen, MS, Blinkenberg, M, Koch-Henriksen, N, et al. Implications of the International Paediatric Multiple Sclerosis Study Group consensus criteria for paediatric acute disseminated encephalomyelitis: a nationwide validation study. Dev Med Child Neurol 2018;60:1123–1131.Google Scholar
Panicker, JN, Nagaraja, D, Kovoor, JM, Subbakrishna, DK. Descriptive study of acute disseminated encephalomyelitis and evaluation of functional outcome predictors. J Postgrad Med 2010;56:12–16.Google Scholar
Graus, F, Titulaer, MJ, Balu, R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391–404.CrossRefGoogle ScholarPubMed
Alper, G, Heyman, R, Wang, L. Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow-up: comparison of presenting features. Dev Med Child Neurol 2009;51:480–486.CrossRefGoogle ScholarPubMed
Fridinger, SE, Alper, G. Defining encephalopathy in acute disseminated encephalomyelitis. J Child Neurol 2014;29:751–755.CrossRefGoogle ScholarPubMed
Tenembaum, S, Chamoles, N, Fejerman, N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002;59:1224–1231.CrossRefGoogle ScholarPubMed
Lim, KE, Hsu, YY, Hsu, WC, Chan, CY. Multiple complete ring-shaped enhanced MRI lesions in acute disseminated encephalomyelitis. Clinical imaging 2003;27:281–284.CrossRefGoogle ScholarPubMed
Tenembaum, S, Chitnis, T, Ness, J, Hahn, JS. Acute disseminated encephalomyelitis. Neurology 2007;68:S23–S36.Google Scholar
Zhang, L, Wu, A, Zhang, B, et al. Comparison of deep gray matter lesions on magnetic resonance imaging among adults with acute disseminated encephalomyelitis, multiple sclerosis, and neuromyelitis optica. Mult Scler 2014;20:418–423.Google Scholar
Lu, Z, Zhang, B, Qiu, W, et al. Comparative brain stem lesions on MRI of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. PLoS One 2011;6:e22766.CrossRefGoogle ScholarPubMed
Wong, YYM, van Pelt, ED, Ketelslegers, IA, et al. Evolution of MRI abnormalities in paediatric acute disseminated encephalomyelitis. Eur J Paediatr Neurol 2017;21:300–304.Google Scholar
Brilot, F, Dale, RC, Selter, RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009;66:833–842.CrossRefGoogle ScholarPubMed
Baumann, M, Sahin, K, Lechner, C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015;86:265–272.Google Scholar
Greenlee, JE. Encephalitis and postinfectious encephalitis. Continuum (Minneapolis, Minn) 2012;18:1271–1289.Google Scholar
Hart, MN, Earle, KM. Haemorrhagic and perivenous encephalitis: a clinical-pathological review of 38 cases. J Neurol Neurosurg Psychiatry 1975;38:585–591.Google Scholar
Young, NP, Weinshenker, BG, Parisi, JE, et al. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain 2010;133:333–348.Google Scholar
Waters, P, Fadda, G, Woodhall, M, et al. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol 2020;77:82–93.Google Scholar
Kennedy, PG. Viral encephalitis: causes, differential diagnosis, and management. J Neurol Neurosurg Psychiatry 2004;75(Suppl. 1):i10–i15.Google Scholar
Titulaer, MJ, Hoftberger, R, Iizuka, T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014;75:411–428.CrossRefGoogle ScholarPubMed
Martinez-Hernandez, E, Guasp, M, Garcia-Serra, A, et al. Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology 2020;94:e2302–2310.CrossRefGoogle ScholarPubMed
Spatola, M, Petit-Pedrol, M, Simabukuro, MM, et al. Investigations in GABAa receptor antibody-associated encephalitis. Neurology 2017;88:1012–1020.Google Scholar
Dorr, J, Krautwald, S, Wildemann, B, et al. Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol 2013;9:307–316.Google Scholar
Kleffner, I, Dorr, J, Ringelstein, M, et al. Diagnostic criteria for Susac syndrome. J Neurol Neurosurg Psychiatry 2016;87:1287–1295.Google Scholar
Siva, A, Saip, S. The spectrum of nervous system involvement in Behcet’s syndrome and its differential diagnosis. J Neurol 2009;256:513–529.Google Scholar
Kocer, N, Islak, C, Siva, A, et al. CNS involvement in neuro-Behcet syndrome: an MR study. Am J Neuroradiol 1999;20:1015–1024.Google Scholar
Uygunoglu, U, Zeydan, B, Ozguler, Y, et al. Myelopathy in Behcet’s disease: the bagel sign. Ann Neurol 2017;82:288–298.Google Scholar
Twilt, M, Benseler, SM. CNS vasculitis in children. Mult Scler Relat Disord 2013;2:162–171.Google Scholar
Neuteboom, RF, Boon, M, Catsman Berrevoets, CE, et al. Prognostic factors after a first attack of inflammatory CNS demyelination in children. Neurology 2008;71:967–973.CrossRefGoogle ScholarPubMed
Banwell, B, Bar-Or, A, Arnold, DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011;10:436–445.Google Scholar
Banwell, B, Krupp, L, Kennedy, J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007;6:773–781.Google Scholar
Peche, SS, Alshekhlee, A, Kelly, J, Lenox, J, Mar, S. A long-term follow-up study using IPMSSG criteria in children with CNS demyelination. Pediatr Neurol 2013;49:329–334.Google Scholar
Mar, S, Lenox, J, Benzinger, T, Brown, S, Noetzel, M. Long-term prognosis of pediatric patients with relapsing acute disseminated encephalomyelitis. J Child Neurol 2010;25:681–688.Google Scholar
Barkhof, F, Filippi, M, Miller, DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059–2069.Google Scholar
Callen, DJ, Shroff, MM, Branson, HM, et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology 2009;72:968–973.Google Scholar
Verhey, LH, Branson, HM, Shroff, MM, et al. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol 2011;10:1065–1073.Google Scholar
Fadda, G, Brown, RA, Longoni, G, et al. MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health 2018;2:191–204.Google Scholar
Pohl, D, Tenembaum, S. Treatment of acute disseminated encephalomyelitis. Curr Treat Opt Neurol 2012;14:264–275.CrossRefGoogle ScholarPubMed
Anlar, B, Basaran, C, Kose, G, et al. Acute disseminated encephalomyelitis in children: outcome and prognosis. Neuropediatrics 2003;34:194–199.Google Scholar
Gadian, J, Kirk, E, Holliday, K, Lim, M, Absoud, M. Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders. Dev Med Child Neurol 2017;59:136–144.CrossRefGoogle ScholarPubMed
Weiner, HL, Dau, PC, Khatri, BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989;39:1143–1149.CrossRefGoogle ScholarPubMed
Weinshenker, BG, O’Brien, PC, Petterson, TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878–886.3.0.CO;2-Q>CrossRefGoogle ScholarPubMed
Absoud, M, Parslow, RC, Wassmer, E, et al. Severe acute disseminated encephalomyelitis: a paediatric intensive care population-based study. Mult Scler 2011;17:1258–1261.Google Scholar
Ahmed, AI, Eynon, CA, Kinton, L, Nicoll, JA, Belli, A. Decompressive craniectomy for acute disseminated encephalomyelitis. Neurocrit Care 2010;13:393–395.Google Scholar
Dombrowski, KE, Mehta, AI, Turner, DA, McDonagh, DL. Life-saving hemicraniectomy for fulminant acute disseminated encephalomyelitis. Br J Neurosurg 2011;25:249–252.Google Scholar
Granget, E, Milh, M, Pech-Gourg, G, et al. Life-saving decompressive craniectomy for acute disseminated encephalomyelitis in a child: a case report. Childs Nerv Syst 2012;28:1121–1124.Google Scholar
Nishiyama, M, Nagase, H, Tomioka, K, et al. Clinical time course of pediatric acute disseminated encephalomyelitis. Brain Dev 2019;41:531–537.Google Scholar
Suppiej, A, Cainelli, E, Casara, G, et al. Long-term neurocognitive outcome and quality of life in pediatric acute disseminated encephalomyelitis. Pediatr Neurol 2014;50:363–367.Google Scholar
Shilo, S, Michaeli, O, Shahar, E, Ravid, S. Long-term motor, cognitive and behavioral outcome of acute disseminated encephalomyelitis. Eur J Paediatr Neurol 2016;20:361–367.Google Scholar
Burton, KLO, Williams, TA, Catchpoole, SE, Brunsdon, RK. Long-term neuropsychological outcomes of childhood onset acute disseminated encephalomyelitis (ADEM): a meta-analysis. Neuropsychol Rev 2017;27:124–133.Google Scholar
Iype, M, Ts, A, Kunju, PM, et al. Factors related to long term motor, behavioral, and scholastic outcome in children with acute disseminated encephalomyelitis. Pediatr Neurol 2018;89:49–57.Google Scholar
Rossor, T, Benetou, C, Wright, S, et al. Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis. Mult Scler 2020;26:333–342.Google Scholar
Kariyawasam, S, Singh, RR, Gadian, J, et al. Clinical and radiological features of recurrent demyelination following acute disseminated encephalomyelitis (ADEM). Mult Scler Relat Disord 2015;4:451–456.Google Scholar
Wong, YYM, Hacohen, Y, Armangue, T, et al. Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome. Eur J Neurol 2018;25:782–786.Google Scholar
Hacohen, Y, Absoud, M, Deiva, K, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm 2015;2:e81.Google Scholar
Reindl, M, Di Pauli, F, Rostasy, K, Berger, T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013;9:455–461.Google Scholar
Ketelslegers, IA, Van Pelt, DE, Bryde, S, et al. Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler 2015;21:1513–1520.CrossRefGoogle Scholar
Jurynczyk, M, Messina, S, Woodhall, MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 2017;140:3128–3138.Google Scholar
Hegen, H, Reindl, M. Recent developments in MOG-IgG associated neurological disorders. Therapeut Adv Neurologic Disord 2020;13:1756286420945135.Google Scholar
Lebar, R, Baudrimont, M, Vincent, C. Chronic experimental autoimmune encephalomyelitis in the guinea pig: presence of anti-M2 antibodies in central nervous system tissue and the possible role of M2 autoantigen in the induction of the disease. J Autoimmun 1989;2:115–132.CrossRefGoogle ScholarPubMed
Lebar, R, Lubetzki, C, Vincent, C, Lombrail, P, Boutry, JM. The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol 1986;66:423–434.Google Scholar
Linington, C, Bradl, M, Lassmann, H, Brunner, C, Vass, K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988;130:443–454.Google Scholar
Kerlero de Rosbo, N, Mendel, I, Ben-Nun, A. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes. Eur J Immunol 1995;25:985–993.Google Scholar
Lalive, PH, Molnarfi, N, Benkhoucha, M, Weber, MS, Santiago-Raber, ML. Antibody response in MOG (35–55) induced EAE. J Neuroimmunol 2011;240–241:28–33.CrossRefGoogle ScholarPubMed
Iglesias, A, Bauer, J, Litzenburger, T, Schubart, A, Linington, C. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 2001;36:220–234.Google Scholar
Bourquin, C, Iglesias, A, Berger, T, Wekerle, H, Linington, C. Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis. Eur J Immunol 2000;30:3663–3671.Google Scholar
Brunner, C, Lassmann, H, Waehneldt, TV, Matthieu, JM, Linington, C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats. J Neurochem 1989;52:296–304.Google Scholar
Reindl, M, Linington, C, Brehm, U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999;122:2047–2056.Google Scholar
Berger, T, Rubner, P, Schautzer, F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349:139–145.Google Scholar
Karni, A, Bakimer-Kleiner, R, Abramsky, O, Ben-Nun, A. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol 1999;56:311–315.Google Scholar
Mantegazza, R, Cristaldini, P, Bernasconi, P, et al. Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association. Int Immunol 2004;16:559–565.Google Scholar
von Budingen, HC, Hauser, SL, Fuhrmann, A, et al. Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination. Proc Natl Acad Sci USA 2002;99:8207–8212.CrossRefGoogle ScholarPubMed
O’Connor, KC, McLaughlin, KA, De Jager, PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13:211–217.Google Scholar
Jarius, S, Paul, F, Aktas, O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018;15:134.Google Scholar
Reindl, M, Schanda, K, Woodhall, M, et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 2020;7:e674.Google Scholar
Sepulveda, M, Armangue, T, Martinez-Hernandez, E, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol 2016;263:1349–1360.CrossRefGoogle ScholarPubMed
Jarius, S, Ruprecht, K, Kleiter, I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016;13:279.Google Scholar
Waters, P, Woodhall, M, O’Connor, KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015;2:e89.CrossRefGoogle ScholarPubMed
Pedreno, M, Sepulveda, M, Armangue, T, et al. Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Mult Scler Relat Disord 2019;28:230–234.Google Scholar
Waters, PJ, Komorowski, L, Woodhall, M, et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology 2019;92:e1250–e1255.Google Scholar
Duignan, S, Wright, S, Rossor, T, et al. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 2018;60:958–962.Google Scholar
Armangue, T, Olive-Cirera, G, Martinez-Hernandez, E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol 2020;19:234–246.Google Scholar
de Mol, CL, Wong, Y, van Pelt, ED, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler 2020;26:806–814.Google Scholar
O’Connell, K, Hamilton-Shield, A, Woodhall, M, et al. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. J Neurol Neurosurg Psychiatry 2020;91:1126–1128.Google Scholar
Hennes, EM, Baumann, M, Schanda, K, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 2017;89:900–908.CrossRefGoogle ScholarPubMed
Cobo-Calvo, A, Ruiz, A, Maillart, E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 2018;90:e1858–e1869.Google Scholar
Kim, SM, Woodhall, MR, Kim, JS, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2015;2:e163.Google Scholar
Ogawa, R, Nakashima, I, Takahashi, T, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 2017;4:e322.Google Scholar
Cobo-Calvo, A, Ayrignac, X, Kerschen, P, et al. Cranial nerve involvement in patients with MOG antibody-associated disease. Neurol Neuroimmunol Neuroinflamm 2019;6:e543.Google Scholar
Jarius, S, Kleiter, I, Ruprecht, K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement – frequency, presentation and outcome. J Neuroinflammation 2016;13:281.Google Scholar
Katsuse, K, Kurihara, M, Sugiyama, Y, et al. Aphasic status epilepticus preceding tumefactive left hemisphere lesion in anti-MOG antibody associated disease. Mult Scler Relat Disord 2019;27:91–94.Google Scholar
Miyaue, N, Yamanishi, Y, Tada, S, et al. A case of ADEM-like presentation with anti-MOG antibody following tumefactive demyelinating lesion. Mult Scler Relat Disord 2019;31:62–64.CrossRefGoogle ScholarPubMed
Berzero, G, Taieb, G, Marignier, R, et al. CLIPPERS mimickers: relapsing brainstem encephalitis associated with anti-MOG antibodies. Eur J Neurol 2018;25:e16–e17.Google Scholar
Bruijstens, AL, Wong, YYM, van Pelt, DE, et al. HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population. Neurol Neuroimmunol Neuroinflamm 2020;7:e702.Google Scholar
Jarius, S, Ruprecht, K, Kleiter, I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016;13:280.Google Scholar
Jurynczyk, M, Geraldes, R, Probert, F, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain 2017;140:617–627.Google Scholar
Jurynczyk, M, Tackley, G, Kong, Y, et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry 2017;88:132–136.Google Scholar
Huppke, P, Rostasy, K, Karenfort, M, et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler 2013;19:941–946.Google Scholar
Baumann, M, Hennes, EM, Schanda, K, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases. Mult Scler 2016;22:1821–1829.Google Scholar
Serra, M, Presicci, A, Fucci, M, et al. Acute disseminated encephalomyelitis followed by optic neuritis: a rare syndrome of uncertain treatment and prognosis. Neuropediatrics 2020;51:286–291.Google Scholar
Biotti, D, Bonneville, F, Tournaire, E, et al. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J Neurol 2017;264:2173–2175.Google Scholar
Chen, JJ, Flanagan, EP, Jitprapaikulsan, J, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 2018;195:8–15.Google Scholar
Lee, HJ, Kim, B, Waters, P, et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation 2018;15:302.Google Scholar
Chalmoukou, K, Alexopoulos, H, Akrivou, S, et al. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2015;2:e131.Google Scholar
Petzold, A, Plant, GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 2014;261:17–26.Google Scholar
Narayan, RN, McCreary, M, Conger, D, Wang, C, Greenberg, BM. Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients. Mult Scler Relat Disord 2019;28:86–90.Google Scholar
Shor, N, Aboab, J, Maillart, E, et al. Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients. Eur J Neurol 2020;27:384–391.Google Scholar
Ramanathan, S, Prelog, K, Barnes, EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 2016;22:470–482.CrossRefGoogle ScholarPubMed
Purvin, V, Kawasaki, A, Jacobson, DM. Optic perineuritis: clinical and radiographic features. Arch Ophthalmol 2001;119:1299–1306.Google Scholar
Jang, Y, Kim, SM, Yun, YI, et al. Comparison between optic neuritis associated with antibody against myelin oligodendrocyte glycoprotein and presumed idiopathic optic perineuritis. Neurol Sci 2020;41:2755–2760.Google Scholar
Ramanathan, S, Fraser, C, Curnow, SR, et al. Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity. Eur J Neurol 2019;26:1137-e75.Google Scholar
Sepulveda, M, Aldea, M, Escudero, D, et al. Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler 2018:24:1843–1851.Google Scholar
Sepulveda, M, Armangue, T, Sola-Valls, N, et al. Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 2016;3:e225.Google Scholar
Kitley, J, Waters, P, Woodhall, M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014;71:276–283.Google Scholar
Dubey, D, Pittock, SJ, Krecke, KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 2019;76:301–309.Google Scholar
Hacohen, Y, Nishimoto, Y, Fukami, Y, et al. Paediatric brainstem encephalitis associated with glial and neuronal autoantibodies. Dev Med Child Neurol 2016;58:836–841.Google Scholar
Banks, SA, Morris, PP, Chen, JJ, et al. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry 2020. doi: 10.1136/jnnp-2020-325121.Google Scholar
Iorio, R, Lucchinetti, CF, Lennon, VA, et al. Intractable nausea and vomiting from autoantibodies against a brain water channel. Clin Gastroenterol Hepatol 2013;11:240–245.Google Scholar
Kunchok, A, Krecke, KN, Flanagan, EP, et al. Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)? Neurology 2020;94:85–88.Google Scholar
Durozard, P, Rico, A, Boutiere, C, et al. Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol 2020;87:256–266.Google Scholar
Budhram, A, Mirian, A, Le, C, et al. Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J Neurol 2019;266:2481–2487.Google Scholar
Hamid, SHM, Whittam, D, Saviour, M, et al. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol 2018;75:65–71.Google Scholar
Wang, L, ZhangBao, J, Zhou, L, et al. Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China. Eur J Neurol 2019;26:168–174.Google Scholar
Takai, Y, Misu, T, Kaneko, K, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain 2020;143:1431–1446.Google Scholar
Ikeda, T, Yamada, K, Ogawa, R, et al. The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies: a case report. J Neurol Sci 2018;392:113–115.Google Scholar
Salama, S, Khan, M, Pardo, S, Izbudak, I, Levy, M. MOG antibody-associated encephalomyelitis/encephalitis. Mult Scler 2019;25:1427–1433.Google Scholar
Wegener-Panzer, A, Cleaveland, R, Wendel, EM, et al. Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies. Neurol Neuroimmunol Neuroinflamm 2020;7:e731.Google Scholar
Robinson, CP, Busl, KM. Neurologic manifestations of severe respiratory viral contagions. Crit Care Explor 2020;2:e0107.Google Scholar
Johns, TG, Bernard, CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 1999;72:1–9.Google Scholar
Delarasse, C, Daubas, P, Mars, LT, et al. Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. J Clin Invest 2003;112:544–553.CrossRefGoogle ScholarPubMed
Dale, RC, Tantsis, EM, Merheb, V, et al. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm 2014;1:e12.Google Scholar
Peschl, P, Schanda, K, Zeka, B, et al. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation 2017;14:208.CrossRefGoogle ScholarPubMed
Wang, JJ, Jaunmuktane, Z, Mummery, C, et al. Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD. Neurology 2016;87:229–231.Google Scholar
Kortvelyessy, P, Breu, M, Pawlitzki, M, et al. ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports. Neurol Neuroimmunol Neuroinflamm 2017;4:e335.Google Scholar
Spadaro, M, Gerdes, LA, Mayer, MC, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2015;2:295–301.Google Scholar
Lucchinetti, C, Bruck, W, Parisi, J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707–717.Google Scholar
Höftberger, R, Guo, Y, Flanagan, EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 2020;139:875–892.Google Scholar
Saadoun, S, Waters, P, Owens, GP, et al. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2014;2:35.Google Scholar
Kinzel, S, Weber, MS. The role of peripheral CNS-directed antibodies in promoting inflammatory CNS demyelination. Brain Sci 2017;7:70.Google Scholar
Kinzel, S, Lehmann-Horn, K, Torke, S, et al. Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathol 2016;132:43–58.Google Scholar
Bonnan, M, Valentino, R, Debeugny, S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018;89:346–351.Google Scholar
Hacohen, Y, Banwell, B. Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Opt Neurol 2019;21:2.Google Scholar
Ramanathan, S, Mohammad, S, Tantsis, E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 2018;89:127–137.Google Scholar
Hacohen, Y, Wong, YY, Lechner, C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2018;75:478–487.Google Scholar
Hyun, JW, Woodhall, MR, Kim, SH, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry 2017;88:811–817.Google Scholar
Probstel, AK, Dornmair, K, Bittner, R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011;77:580–588.Google Scholar
Oliveira, LM, Apóstolos-Pereira, SL, Pitombeira, MS et al. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler 2019;25:1907–1914.Google Scholar
Lopez-Chiriboga, AS, Majed, M, Fryer, J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol 2018;75:1355–1363.Google Scholar
Li, S, Ren, H, Xu, Y, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study. Neurol Neuroimmunol Neuroinflamm 2020;7:e705.Google Scholar
Chen, JJ, Flanagan, EP, Bhatti, MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 2020;95:e111–e120.Google Scholar
Whittam, DH, Cobo-Calvo, A, Lopez-Chiriboga, AS, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord 2020;44:102251.Google Scholar
Levy, M, Fujihara, K, Palace, J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 2021;20:60–67.Google Scholar
Rigal, J, Pugnet, G, Ciron, J, Lépine, Z, Biotti, D. Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: a case-series. Mult Scler Relat Disord 2020;46:102483.Google Scholar
Elsbernd, PM, Hoffman, WR, Carter, JL, Wingerchuk, DM. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review. Mult Scler Relat Disord 2020;48:102696.Google Scholar
Phillips, OR, Joshi, SH, Narr, KL, et al. Superficial white matter damage in anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry 2018;89:518–525.Google Scholar
Graus, F, Keime-Guibert, F, Rene, R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:1138–1148.Google Scholar
Bernal, F, Graus, F, Pifarre, A, et al. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol (Berl) 2002;103:509–515.Google Scholar
Henson, RA, Hoffman, HL, Urich, H. Encephalomyelitis with carcinoma. Brain 1965;88:449–464.Google Scholar
Honnorat, J, Cartalat-Carel, S, Ricard, D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009;80:412–416.Google Scholar
Ricard, D, Rogemond, V, Charrier, E, et al. Isolation and expression pattern of human Unc-33-like phosphoprotein 6/collapsin response mediator protein 5 (Ulip6/CRMP5): coexistence with Ulip2/CRMP2 in Sema3a- sensitive oligodendrocytes. J Neurosci 2001;21:7203–7214.Google Scholar
Ricard, D, Stankoff, B, Bagnard, D, et al. Differential expression of collapsin response mediator proteins (CRMP/ULIP) in subsets of oligodendrocytes in the postnatal rodent brain. Molec Cell Neurosci 2000;16:324–337.Google Scholar
Cohen, DA, Bhatti, MT, Pulido, JS, et al. Collapsin response-mediator protein 5-associated retinitis, vitritis, and optic disc edema. Ophthalmology 2020;127:221–229.Google Scholar
Keegan, BM, Pittock, SJ, Lennon, VA. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol 2008;63:531–534.Google Scholar
Ducray, F, Roos-Weil, R, Garcia, PY, et al. Devic’s syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2007;78:325–327.Google Scholar
Vernino, S, Tuite, P, Adler, CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002;51:625–630.Google Scholar
Yu, Z, Kryzer, TJ, Griesmann, GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146–154.Google Scholar
Cross, SA, Salomao, DR, Parisi, JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003;54:38–50.Google Scholar
Antoine, JC, Honnorat, J, Vocanson, C, et al. Posterior uveitis, paraneoplastic encephalomyelitis and auto- antibodies reacting with developmental protein of brain and retina. J Neurol Sci 1993;117:215–223.Google Scholar
Margolin, E, Flint, A, Trobe, JD. High-titer collapsin response-mediating protein-associated (CRMP-5) paraneoplastic optic neuropathy and vitritis as the only clinical manifestations in a patient with small cell lung carcinoma. J Neuroophthalmol 2008;28:17–22.Google Scholar
Morita, M, Fukuhara, T, Takahashi, H, Maemondo, M. Small cell lung cancer and progressive retinopathy. BMJ Case Rep 2014;2014:bcr2014205888.Google Scholar
Murphy, MA, Thirkill, CE, Hart, WM Jr. Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma. J Neuroophthalmol 1997;17:77–83.Google Scholar
Luiz, JE, Lee, AG, Keltner, JL, Thirkill, CE, Lai, EC. Paraneoplastic optic neuropathy and autoantibody production in small-cell carcinoma of the lung. J Neuroophthalmol 1998;18:178–181.CrossRefGoogle ScholarPubMed
Dubey, D, Lennon, VA, Gadoth, A, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology 2018;90:e103–e110.Google Scholar
Camdessanche, JP, Antoine, JC, Honnorat, J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies: a clinical and electrophysiological study of 20 patients. Brain 2002;125:166–175.Google Scholar
Moss, HE, Liu, GT, Dalmau, J. Glazed (vision) and confused. Survey Ophthalmol 2010;55:169–173.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×